Clinical Trial Update: Pilot Study of RNS60 in Allergen-induced Bronchoconstriction [Phase 2]

View source ↗

Summary

The Phase 2 pilot trial of RNS60 for allergen-induced bronchoconstriction in asthma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• RNS60

Snippet

Sponsor: Revalesio Corporation | Conditions: Asthma | Phase 2 | Status: WITHDRAWN